YU50402A - Pyrido(2,3-d)pyrimidine-2,7-diamine kinase inhibitors - Google Patents

Pyrido(2,3-d)pyrimidine-2,7-diamine kinase inhibitors

Info

Publication number
YU50402A
YU50402A YU50402A YUP50402A YU50402A YU 50402 A YU50402 A YU 50402A YU 50402 A YU50402 A YU 50402A YU P50402 A YUP50402 A YU P50402A YU 50402 A YU50402 A YU 50402A
Authority
YU
Yugoslavia
Prior art keywords
substituted lower
compounds
substituted
nr9r10
cyano
Prior art date
Application number
YU50402A
Other languages
Serbo-Croatian (sh)
Inventor
Richard John Booth
Ellen Myra Dobrusin
Vara Prasad Venkata N. Josyula
Dennis Joseph Mcnamara
Peter Laurence Toogood
Original Assignee
Warner-Lambert Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company filed Critical Warner-Lambert Company
Publication of YU50402A publication Critical patent/YU50402A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Abstract

Disclosed are compounds of the formula (I) wherein: R2, R7, R13, R14 and R15 are independently hydrogen, or (un)substituted lower alkyl, (un)substitued lower alkenyl, (un)substituted lower alkynyl, or (un)substituted -(CH2)nR12; R5 is halogen, cyano, nitro, -R9, -NR9R10, or -OR9; R6 is halogen, cyano, nitro, -R9, -NR9R10, -OR9, -CO2R9, -COR9, -CONR9R10, -NR9COR10, (un)substituted lower alkenyl, or (un)substituted lower alkynyl; R8 is -CO2R13, -COR13, -CONR13R14, -CSNR13R14, -C(NR13)NR14R15, -SO3R13, -SO2R13, -SO2NR13R14, -PO3R13R14, -POR13R14, -PO(NR13R14)2; R9 and R10 are independently hydrogen or (un)substituted lower alkyl; R11 is a heteroaryl or a heterocyclic group; R12 is a cycloalkyl, a heterocyclic, an aryl, or a heteroaryl group; and n is 0,1, 2, or 3. These compounds and their pharmaceutical compositions are useful for treating cell proliferative disorders, such as cancer and restenosis. These compounds are potent inhibitors of cdks and growth factor-mediated kinases.
YU50402A 2000-01-25 2001-01-23 Pyrido(2,3-d)pyrimidine-2,7-diamine kinase inhibitors YU50402A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17826100P 2000-01-25 2000-01-25

Publications (1)

Publication Number Publication Date
YU50402A true YU50402A (en) 2005-11-28

Family

ID=22651853

Family Applications (1)

Application Number Title Priority Date Filing Date
YU50402A YU50402A (en) 2000-01-25 2001-01-23 Pyrido(2,3-d)pyrimidine-2,7-diamine kinase inhibitors

Country Status (34)

Country Link
EP (1) EP1254137A1 (en)
JP (1) JP4047010B2 (en)
KR (1) KR20020065939A (en)
CN (1) CN1395578A (en)
AP (1) AP2002002586A0 (en)
AR (1) AR030044A1 (en)
AU (1) AU2542501A (en)
BG (1) BG106850A (en)
BR (1) BR0107751A (en)
CA (1) CA2397961C (en)
CO (1) CO5261549A1 (en)
CR (1) CR6706A (en)
CZ (1) CZ20022475A3 (en)
DZ (1) DZ3266A1 (en)
EA (1) EA200200643A1 (en)
EE (1) EE200200405A (en)
GT (1) GT200100016A (en)
HN (1) HN2001000013A (en)
HU (1) HUP0204141A3 (en)
IL (1) IL150545A0 (en)
IS (1) IS6443A (en)
MA (1) MA26868A1 (en)
MX (1) MXPA02007221A (en)
NO (1) NO20023527L (en)
OA (1) OA12161A (en)
PA (1) PA8510701A1 (en)
PE (1) PE20011066A1 (en)
PL (1) PL356802A1 (en)
SK (1) SK10632002A3 (en)
SV (1) SV2002000294A (en)
TN (1) TNSN01014A1 (en)
WO (1) WO2001055147A1 (en)
YU (1) YU50402A (en)
ZA (1) ZA200205879B (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
JP4524072B2 (en) 2000-10-23 2010-08-11 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー New compounds
PE20030008A1 (en) * 2001-06-19 2003-01-22 Bristol Myers Squibb Co DUAL INHIBITORS OF PDE 7 AND PDE 4
US7629350B2 (en) 2002-04-19 2009-12-08 Smithkline Beecham Corporation Compounds
NZ539823A (en) * 2002-11-28 2008-04-30 Schering Aktiengessellschaft Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents
US7157455B2 (en) * 2003-02-10 2007-01-02 Hoffmann-La Roche Inc. 4-Aminopyrimidine-5-one derivatives
TW200502236A (en) 2003-03-28 2005-01-16 Hoffmann La Roche Novel pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents
FR2873118B1 (en) 2004-07-15 2007-11-23 Sanofi Synthelabo PYRIDO-PYRIMIDINE DERIVATIVES, THEIR APPLICATION IN THERAPEUTICS
JP2008518883A (en) * 2004-09-21 2008-06-05 エフ．ホフマン−ラ ロシュ アーゲー 6- (2-Alkyl-phenyl) -pyrido [2,3-D] pyrimidines useful as protein kinase inhibitors
AR053450A1 (en) 2005-03-25 2007-05-09 Glaxo Group Ltd DERIVATIVES OF 3,4-DIHYDRO-PYRIMID (4,5-D) PYRIMIDIN-2- (1H) -ONA 1,5,7 TRISUSTITUTED AS INHIBITORS OF QUINASE P38
EP1868612A4 (en) 2005-03-25 2010-03-24 Glaxo Group Ltd Novel compounds
EA200702073A1 (en) 2005-03-25 2008-12-30 Глэксо Груп Лимитед Method of producing pyrido [2,3-d] pyrimidine-7-bp and 3,4-dihidropyrimido [4,5-d] pyrmidin-2 (1h) -onovy derivatives
AR053346A1 (en) 2005-03-25 2007-05-02 Glaxo Group Ltd COMPOSITE DERIVED FROM 8H -PIRIDO (2,3-D) PIRIMIDIN -7 ONA 2,4,8- TRISUSTITUTED PHARMACEUTICAL COMPOSITION AND USE TO PREPARE A COMPOSITION FOR TREATMENT AND PROFILXIS OF A DISEASE MEDIATED BY KINASE CSBP / RK / P38
FR2887882B1 (en) * 2005-07-01 2007-09-07 Sanofi Aventis Sa PYRIDO [2,3-D] PYRIMIDINE DERIVATIVES, THEIR PREPARATION, THEIR THERAPEUTIC APPLICATION
KR100962723B1 (en) * 2005-07-21 2010-06-09 에프. 호프만-라 로슈 아게 Pyrido[2,3-d]pyrimidine-2,4-diamine compounds as ptp1b inhibitors
PL2099797T3 (en) 2005-08-09 2011-03-31 Irm Llc Compounds and compositions as protein kinase inhibitors
FR2896246B1 (en) 2006-01-13 2008-08-15 Sanofi Aventis Sa PYRIDO-PYRIMIDONE DERIVATIVES, THEIR PREPARATION, THEIR THERAPEUTIC APPLICATION
EP1914234A1 (en) 2006-10-16 2008-04-23 GPC Biotech Inc. Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors
JO2985B1 (en) 2006-12-20 2016-09-05 Takeda Pharmaceuticals Co MAPK/ERK Kinase Inhibitors
FR2910813B1 (en) 2006-12-28 2009-02-06 Sanofi Aventis Sa NEW THERAPEUTIC USE FOR THE TREATMENT OF LEUKEMIA
EP2112150B1 (en) 2008-04-22 2013-10-16 Forma Therapeutics, Inc. Improved raf inhibitors
EA201100879A1 (en) * 2008-12-01 2012-01-30 Мерк Патент Гмбх PYRIDOPYRIMIDINE DERIVATIVES AS AUTOTAXIN INHIBITORS
GB201104267D0 (en) 2011-03-14 2011-04-27 Cancer Rec Tech Ltd Pyrrolopyridineamino derivatives
GB201216018D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Pharmacologically active compounds
GB201216017D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Inhibitor compounds
US9815847B2 (en) 2013-03-14 2017-11-14 Icahn School Of Medicine At Mount Sinai Pyrimidine compounds as kinase inhibitors
GB201403536D0 (en) 2014-02-28 2014-04-16 Cancer Rec Tech Ltd Inhibitor compounds
KR101671404B1 (en) * 2014-09-02 2016-11-02 한국원자력의학원 Pyrimidine derivatives having anti-cancer effect, combination therapeutic effect with radiation, and anti-diabetic effect, and PPAR activity, and medical use thereof
CN107286180B (en) * 2016-04-11 2019-07-02 上海勋和医药科技有限公司 Miscellaneous generation Pyridopyrimidinone derivatives are as CDK inhibitor and its application
GB201709840D0 (en) 2017-06-20 2017-08-02 Inst Of Cancer Research: Royal Cancer Hospital Methods and medical uses

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL115256A0 (en) * 1994-11-14 1995-12-31 Warner Lambert Co 6-Aryl pyrido (2,3-d) pyrimidines and naphthyridines and their use
TJ342B (en) * 1994-11-14 2002-10-06 Warner Lambert Co Derivatives of 6-aryl pyrido Ä2,3-dÜ pyrimidines and naphthyridines pharmaceutical composition possess inhibiting effect of cellular proliferation pr ovoking protein tyrosine kinase and method of inhibiting cellular proliferation
US5620981A (en) * 1995-05-03 1997-04-15 Warner-Lambert Company Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
ES2310039T3 (en) * 1998-05-26 2008-12-16 Warner-Lambert Company Llc BICYCLE PYRIMIDINES AND BICYCLE 3,4-DIHYDROPIRIMIDINS AS INHIBITORS OF CELL PROLIFERATION.

Also Published As

Publication number Publication date
CO5261549A1 (en) 2003-03-31
CA2397961A1 (en) 2001-08-02
NO20023527L (en) 2002-09-10
MXPA02007221A (en) 2002-11-29
MA26868A1 (en) 2004-12-20
PL356802A1 (en) 2004-07-12
CR6706A (en) 2005-04-04
ZA200205879B (en) 2003-09-29
KR20020065939A (en) 2002-08-14
PA8510701A1 (en) 2002-12-11
NO20023527D0 (en) 2002-07-24
TNSN01014A1 (en) 2005-11-10
JP2003523357A (en) 2003-08-05
SV2002000294A (en) 2002-07-16
EA200200643A1 (en) 2002-12-26
PE20011066A1 (en) 2001-10-22
IL150545A0 (en) 2003-02-12
BR0107751A (en) 2002-11-12
JP4047010B2 (en) 2008-02-13
CZ20022475A3 (en) 2003-03-12
OA12161A (en) 2006-05-08
WO2001055147A1 (en) 2001-08-02
CN1395578A (en) 2003-02-05
EP1254137A1 (en) 2002-11-06
AR030044A1 (en) 2003-08-13
AU2542501A (en) 2001-08-07
BG106850A (en) 2003-02-28
HN2001000013A (en) 2001-06-18
HUP0204141A3 (en) 2005-03-29
GT200100016A (en) 2001-10-19
IS6443A (en) 2002-06-25
EE200200405A (en) 2003-12-15
DZ3266A1 (en) 2001-08-02
SK10632002A3 (en) 2003-06-03
CA2397961C (en) 2008-08-26
HUP0204141A2 (en) 2003-04-28
AP2002002586A0 (en) 2002-09-30

Similar Documents

Publication Publication Date Title
YU50402A (en) Pyrido(2,3-d)pyrimidine-2,7-diamine kinase inhibitors
BG106594A (en) Pteridinones as kinase inhibitors
AP2000001964A0 (en) Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation.
MY141739A (en) Substituted quinazoline derivatives as inhibitors of aurora kinases
MXPA02011974A (en) Substituted quinazoline derivatives and their use as inhibitors.
CA2997039C (en) 2,4-bis(nitrogen-containing group)-substituted pyrimidine compound, preparation method and use thereof
SE0202463D0 (en) Novel compounds
RU2005127052A (en) Compounds of thienopyrimidine and their use
GEP20156282B (en) Compounds and compositions as protein kinase inhibitors
NZ627709A (en) Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity
BG107161A (en) 5-alkylpyrido[2,3-d]pyrimidines tyrosine kinase inhibitors
GEP20063915B (en) PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS AND USE THEREOF FOR TREATING p38 KINASE-ASSOCIATED CONDITIONS
IL150883A0 (en) Pyrimidine compounds
BR112015002152B1 (en) COMPOUNDS OF REPLACED PYRROILS ACTIVE AS KINASE INHIBITORS, PROCESS FOR THE PREPARATION OF SUCH COMPOUNDS, PHARMACEUTICAL COMPOSITION, IN VITRO METHOD FOR INHIBITION OF THE ACTIVITY OF KINASE PROTEINS OF THE JAK FAMILY
MXPA05013349A (en) 2-aminopyrimidine derivatives as raf kinase inhibitors.
AR006906A1 (en) SUBSTITUTED INDAZOL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM, USE OF THEM AND INTERMEDIARIES OF SYNTHESIS
UY27198A1 (en) NEW BENCIMIDAZOL ANTI-INFLAMMATORY COMPOUNDS
HUP0300798A2 (en) Substituted-triazolopyrimidines and their use as anticancer agents and pharmaceutical compositions containing them
UA83091C2 (en) Pyrido[2,3-d]pyrimidine-2,4-diamines as pde 2 inhibitors
EP1233950A4 (en) 3,4-DIHYDRO-(1H)QUINAZOLIN-2-ONE COMPOUNDS AS CSBP/P39 kINASE INHIBITORS
YU21404A (en) Substituted benzimidazole compounds and their use for the treatment of cancer
MXPA03004023A (en) Condensed pyrazindione derivatives as pde inhibitors.
DK0888356T3 (en) Condensed 2,3-benzodiazepine derivatives and their use as AMPA receptor inhibitors
AR027035A1 (en) PIRROLES REPLACED
TH53887A (en) Pyrido (2,3-d), pyrimidine-2.7-diamine as a kinase inhibitor.